Jonathan Villena‐Vargas

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

Leonid Cherkassky, Aurore Morello, Jonathan Villena‐Vargas et al. · Journal of Clinical Investigation · 2016 · 1K citations · Full text

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

Prasad S. Adusumilli, Leonid Cherkassky, Jonathan Villena‐Vargas et al. · Science Translational Medicine · 2014 · 552 citations

Prognostic Significance of Adenocarcinoma In Situ, Minimally Invasive Adenocarcinoma, and Nonmucinous Lepidic Predominant Invasive Adenocarcinoma of the Lung in Patients With Stage I Disease

Kyuichi Kadota, Jonathan Villena‐Vargas, Akihiko Yoshizawa et al. · The American Journal of Surgical Pathology · 2014 · 250 citations · Full text

Health Sciences, Advanced Lung Disease, Medicine +15

Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma

Stefan S. Kachala, Adam J. Bograd, Jonathan Villena‐Vargas et al. · Clinical Cancer Research · 2013 · 178 citations · Full text

Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma

Kyuichi Kadota, Yi‐Chen Yeh, Jonathan Villena‐Vargas et al. · CHEST Journal · 2015 · 79 citations · Full text

Immune Evasion, Cancer Immunosurveillance, Oncology +11